Macrolide-Resistant Streptococcus pneumoniae and Streptococcus pyogenes in the Pediatric Population in Germany during 2000-2001
Open Access
- 1 February 2003
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (2) , 682-688
- https://doi.org/10.1128/aac.47.2.489-493.2003
Abstract
In a nationwide study in Germany covering 13 clinical microbiology laboratories, a total of 307 Streptococcus pyogenes (mainly pharyngitis) and 333 Streptococcus pneumoniae (respiratory tract infections) strains were collected from outpatients less than 16 years of age. The MICs of penicillin G, amoxicillin, cefotaxime, erythromycin A, clindamycin, levofloxacin, and telithromycin were determined by the microdilution method. In S. pyogenes isolates, resistance rates were as follows: penicillin, 0%; erythromycin A, 13.7%; and levofloxacin, 0%. Telithromycin showed good activity against S. pyogenes isolates (MIC 90 = 0.25 μg/ml; MIC range, 0.016 to 16 μg/ml). Three strains were found to be telithromycin-resistant (MIC ≥ 4 μg/ml). Erythromycin-resistant strains were characterized for the underlying resistance genotype, with 40.5% having the efflux type mef (A), 38.1% having the erm (A), and 9.5% having the erm (B) genotypes. emm typing of macrolide-resistant S. pyogenes isolates showed emm types 4 (45.2%), 77 (26.2%), and 12 (11.9%) to be predominant. In S. pneumoniae , resistance rates were as follows: penicillin intermediate, 7.5%; penicillin resistant, 0%; erythromycin A, 17.4%; and levofloxacin, 0%. Telithromycin was highly active against pneumococcal isolates (MIC 90 ≤ 0.016 μg/ml; range, 0.016 to 0.5 μg/ml). The overall resistance profile of streptococcal respiratory tract isolates is still favorable, but macrolide resistance is of growing concern in Germany.Keywords
This publication has 30 references indexed in Scilit:
- Susceptibilities to Telithromycin and Six Other Agents and Prevalence of Macrolide Resistance Due to L4 Ribosomal Protein Mutation among 992 Pneumococci from 10 Central and Eastern European CountriesAntimicrobial Agents and Chemotherapy, 2002
- Macrolide-Resistant Streptococcus pneumoniae in Canada during 1998–1999: Prevalence of mef (A) and erm (B) and Susceptibilities to KetolidesAntimicrobial Agents and Chemotherapy, 2001
- Macrolide Resistance inStreptococcus pyogenesIsolates from Throat Infections in the Region of Aachen, GermanyMicrobial Drug Resistance, 2001
- Multilocus Sequence Typing ofStreptococcus pyogenesand the Relationships betweenemmType and CloneInfection and Immunity, 2001
- In Vitro Activities of the Novel Ketolide Telithromycin (HMR 3647) against Erythromycin-Resistant Streptococcus SpeciesAntimicrobial Agents and Chemotherapy, 2001
- Mechanisms of Macrolide Resistance in Clinical Pneumococcal Isolates in FranceAntimicrobial Agents and Chemotherapy, 2001
- Proportion of Invasive Pneumococcal Infections in German Children Preventable by Pneumococcal Conjugate VaccinesClinical Infectious Diseases, 2000
- Mutations in 23S rRNA and Ribosomal Protein L4 Account for Resistance in Pneumococcal Strains Selected In Vitro by Macrolide PassageAntimicrobial Agents and Chemotherapy, 2000
- Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989–94Epidemiology and Infection, 1996
- Infections Caused by Streptococcus pneumoniae: Clinical Spectrum, Pathogenesis, Immunity, and TreatmentClinical Infectious Diseases, 1992